

Eileen M O reilly

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6260603/eileen-m-oreilly-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 271 papers | 12,265 citations | 57 h-index | 105 g-index |
| 300 ext. papers | 16,268 ext. citations | 6.3 avg, IF | 6.37 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 271 | Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 528-528 | 2.2 | 0 |
| 270 | Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements.. <i>Cancer Discovery</i> , 2022 , | 24.4 | 8 |
| 269 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. <i>Cell</i> , 2022 , 185, 563-575.e11 | 56.2 | 11 |
| 268 | Venous Thromboprophylaxis in Surgical Oncology Patients: The Importance of Risk Assessment in the Context of Limited Evidence.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102935 | 2.2 | |
| 267 | Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. <i>Communications Biology</i> , 2021 , 4, 1333 | 6.7 | 1 |
| 266 | Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2021 , | 9.7 | 4 |
| 265 | Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021 , | 2.8 | 1 |
| 264 | Multimodality therapy in metastatic pancreas cancer with a mutation and durable long-term outcome: biology, intervention, or both?. <i>Cancer Biology and Therapy</i> , 2021 , 1-5 | 4.6 | |
| 263 | Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1194-1202 | 9.7 | 8 |
| 262 | Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity. <i>Pancreatology</i> , 2021 , 21, 599-605 | 3.8 | 1 |
| 261 | Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 1277-1286 | 27.4 | 12 |
| 260 | Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2021 , 21, 385 | 4.8 | 4 |
| 259 | Pancreas cancer: Therapeutic trials in metastatic disease. <i>Journal of Surgical Oncology</i> , 2021 , 123, 1475-1488 | 14.8 | 5 |
| 258 | Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. <i>JAMA Oncology</i> , 2021 , 7, 735-738 | 13.4 | 30 |
| 257 | Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021 , 12, 3770 | 17.4 | 10 |
| 256 | Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review. <i>JAMA Surgery</i> , 2021 , 156, 663-672 | 5.4 | 6 |
| 255 | Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021 , 274, 894-901 | 17.8 | 5 |

| | | | |
|-----|---|------|----|
| 254 | Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. <i>Abdominal Radiology</i> , 2021 , 46, 1607-1617 | 3 | 1 |
| 253 | IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa074 | 4.6 | 2 |
| 252 | Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2021 , 127, 1568-1575 | 6.4 | 1 |
| 251 | CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , 2021 , 22, 118-131 | 21.7 | 59 |
| 250 | Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 378-378 | 2.2 | 29 |
| 249 | Pancreatic ductal adenocarcinoma in the era of precision medicine. <i>Seminars in Oncology</i> , 2021 , 48, 19-33 | 3.5 | 4 |
| 248 | Treatment patterns and survival in patients with early-onset pancreatic cancer. <i>Cancer</i> , 2021 , 127, 3566-3578 | 3.7 | 2 |
| 247 | Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2698-2709 | 2.2 | 16 |
| 246 | Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. <i>Cancer</i> , 2021 , 127, 4585-4593 | 6.4 | 2 |
| 245 | Retrospective Case Series Analysis of Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021 , 5, | 3.6 | 3 |
| 244 | Targeting DNA damage repair pathways in pancreas cancer. <i>Cancer and Metastasis Reviews</i> , 2021 , 40, 891-908 | 9.6 | 6 |
| 243 | Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021 , 127, 4393-4402 | 6.4 | 6 |
| 242 | Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2803-2815 | 2.2 | 7 |
| 241 | Pancreatic Cancer: A Review. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 851-862 | 27.4 | 69 |
| 240 | Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10-10 | 2.2 | |
| 239 | A Review of Pancreatic Cancer-Reply.. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 2436-2437 | 27.4 | |
| 238 | Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial. <i>JAMA Network Open</i> , 2020 , 3, e2023500 | 10.4 | 2 |
| 237 | Duration of therapy for locally advanced pancreatic cancer: Does it matter?. <i>Cancer Medicine</i> , 2020 , 9, 4572-4580 | 4.8 | 2 |

| | | | |
|-----|--|------|-----|
| 236 | Reply to N. Fazio. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2467-2468 | 2.2 | 0 |
| 235 | A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma. <i>Oncologist</i> , 2020 , 25, 925-e1603 | 5.7 | 6 |
| 234 | Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2020 , 126, 3939-3949 | 6.4 | 16 |
| 233 | The Evolutionary Origins of Recurrent Pancreatic Cancer. <i>Cancer Discovery</i> , 2020 , 10, 792-805 | 24.4 | 33 |
| 232 | Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , 2020 , 126, 1995-2002 | 6.4 | 9 |
| 231 | Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 41 | 5.3 | 24 |
| 230 | Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1378-1388 | 2.2 | 136 |
| 229 | Reply to Nutritional support in pancreatic cancer. <i>Cancer</i> , 2020 , 126, 1811-1812 | 6.4 | |
| 228 | Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2020 , 33, 1822-1831 | 9.8 | 16 |
| 227 | Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. <i>Clinical Cancer Research</i> , 2020 , 26, 3239-3247 | 12.9 | 58 |
| 226 | NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4661-TPS4661 | 2.2 | 1 |
| 225 | A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS4672-TPS4672 | 2.2 | 15 |
| 224 | Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 648-648 | 2.2 | 1 |
| 223 | Young-onset pancreas cancer (PC) in patients less than or equal to 50 years old at Memorial Sloan Kettering (MSK): Descriptors, genomics, and outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 774-774 | 2.2 | 3 |
| 222 | Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4620-4620 | 2.2 | |
| 221 | Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020 , 132, 112-121 | 7.5 | 12 |
| 220 | Liver and Bile Duct Cancer 2020 , 1314-1341.e11 | | 3 |
| 219 | A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.. <i>Nature Cancer</i> , 2020 , 1, 59-74 | 15.4 | 56 |

| | | | |
|-----|---|------|-----|
| 218 | Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa024 | 4.6 | 4 |
| 217 | Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. <i>Cancer Medicine</i> , 2020 , 9, 8480-8490 | 4.8 | 4 |
| 216 | Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2947-2948 | 2.2 | |
| 215 | Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. <i>Cancer Medicine</i> , 2020 , 9, 6196-6204 | 4.8 | 7 |
| 214 | Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. <i>Cancer</i> , 2020 , 126, 4126-4135 | 6.4 | 0 |
| 213 | Metastatic Pancreatic Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , JCO2001364 | 2.2 | 54 |
| 212 | Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. <i>Cell</i> , 2020 , 182, 1044-1061 | 6.18 | 288 |
| 211 | BRCA1/2 gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies. <i>Chinese Clinical Oncology</i> , 2020 , 9, 64 | 2.3 | 2 |
| 210 | Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020 , 6, 1713-1721 | 13.4 | 13 |
| 209 | Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. <i>Cancer Medicine</i> , 2020 , 9, 7453-7459 | 4.8 | 4 |
| 208 | A mixed methods analysis of patients' advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC). <i>Supportive Care in Cancer</i> , 2020 , 28, 1109-1119 | 3.9 | 1 |
| 207 | Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz078 | 4.6 | 12 |
| 206 | PD-1 Blockade in Advanced Adrenocortical Carcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 71-80 | 2.2 | 61 |
| 205 | Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 800-811 | 4.3 | 52 |
| 204 | New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. <i>Drugs</i> , 2020 , 80, 647-669 | 12.1 | 38 |
| 203 | An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. <i>JAMA Oncology</i> , 2020 , 6, 764-771 | 13.4 | 14 |
| 202 | Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , 2019 , 125, 4426-4434 | 6.4 | 28 |
| 201 | Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1582-1588 | 13.4 | 50 |

| | | | |
|-----|--|------|-----|
| 200 | Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. <i>Annals of Oncology</i> , 2019 , 30, 1959-1968 | 10.3 | 26 |
| 199 | Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 7014-7023 | 12.9 | 25 |
| 198 | Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 317-327 | 59.2 | 826 |
| 197 | Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. <i>Cancer Treatment Reviews</i> , 2019 , 75, 27-38 | 14.4 | 26 |
| 196 | Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 286-295 | 2.2 | 203 |
| 195 | Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2620-2631 | 2.2 | 26 |
| 194 | Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4489-4497 | 37 | 11 |
| 193 | Pancreatic cancer-A disease in need: Optimizing and integrating supportive care. <i>Cancer</i> , 2019 , 125, 3927-3935 | 35 | |
| 192 | Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1431-1438 | 13.4 | 190 |
| 191 | Tumour lineage shapes BRCA-mediated phenotypes. <i>Nature</i> , 2019 , 571, 576-579 | 50.4 | 170 |
| 190 | A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. <i>Cancer Medicine</i> , 2019 , 8, 5148-5157 | 4.8 | 29 |
| 189 | Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution. <i>Hpb</i> , 2019 , 21, 1541-1551 | 3.8 | 9 |
| 188 | Abstract PR02: Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, inNRG1fusion-positive cancers 2019 , | | 17 |
| 187 | Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients 2019 , | | 35 |
| 186 | Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4016-4016 | 2.2 | 6 |
| 185 | Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 202-210 | 7.3 | 179 |
| 184 | Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 720-728 | 59.2 | 322 |
| 183 | Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 937-945 | 12.9 | 15 |

| | | | |
|-----|---|------|-----|
| 182 | Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations. <i>Cancer</i> , 2019 , 125, 575-585 | 6.4 | 23 |
| 181 | Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , 2019 , 25, 2185-2193 | 12.9 | 22 |
| 180 | Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , 2019 , 125, 1441-1448 | 6.4 | 8 |
| 179 | A synonymous germline variant PALB2 c.18G>T (p.Gly6=) disrupts normal splicing in a family with pancreatic and breast cancers. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 79-86 | 4.4 | 3 |
| 178 | Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 121-128 | 3.8 | 13 |
| 177 | Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 1067-1074 | 9.7 | 103 |
| 176 | Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , 2018 , 19, e151-e160 | 21.7 | 31 |
| 175 | Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e315-e321 | 3.8 | 6 |
| 174 | Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2018 , 124, 1374-1382 | 6.4 | 67 |
| 173 | Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018 , 24, 1326-1336 | 12.9 | 198 |
| 172 | Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?. <i>Clinical Cancer Research</i> , 2018 , 24, 2241-2250 | 12.9 | 27 |
| 171 | Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 50-58 | 7.3 | 22 |
| 170 | Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e207-e216 | 3.8 | 6 |
| 169 | A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices. <i>Journal of Pain and Symptom Management</i> , 2018 , 56, 169-177.e1 | 4.8 | 15 |
| 168 | Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. <i>Investigational New Drugs</i> , 2018 , 36, 683-695 | 4.3 | 53 |
| 167 | Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018 , 18, 693 | 4.8 | 41 |
| 166 | Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior. <i>BMC Cancer</i> , 2018 , 18, 769 | 4.8 | 23 |
| 165 | Classification of Pancreatic Cancer: Ready for Practical Application?. <i>Clinical Cancer Research</i> , 2018 , 24, 4355-4356 | 12.9 | 3 |

| | | | |
|-----|--|------|-----|
| 164 | Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018 , 132, LBA-1-LBA-1 | 2.2 | 9 |
| 163 | A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 217-217 | 2.2 | 26 |
| 162 | Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 405-405 | 2.2 | 4 |
| 161 | Nano-liposomal irinotecan and 5-FU/LV (N+F) for the treatment of advanced PDAC: Memorial Sloan Kettering (MSK) Single Cancer Center Evaluation.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 471-471 | 2.2 | |
| 160 | Synthetic Lethality: Achilles Heel in Select Patient Subpopulations 2018 , 257-270 | | |
| 159 | Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2018 , 89, 19-26 | 7.5 | 98 |
| 158 | Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2545-2556 | 2.2 | 129 |
| 157 | Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. <i>Pancreas</i> , 2018 , 47, 1256-1261 | 2.6 | 3 |
| 156 | Acquired resistance to immunotherapy in MMR-D pancreatic cancer 2018 , 6, 127 | | 19 |
| 155 | Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. <i>Cancers</i> , 2018 , 10, | 6.6 | 8 |
| 154 | Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , 2018 , 24, 4154-4161 | 12.9 | 182 |
| 153 | A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 429-440 | 3.5 | 26 |
| 152 | Development of an advance care planning paradigm for advanced cancer: person-centered oncologic care and choices (P-COCC). <i>Psycho-Oncology</i> , 2017 , 26, 866-869 | 3.9 | 13 |
| 151 | Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , 2017 , 116, 697-702 | 8.7 | 49 |
| 150 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2392-2401 | 27.4 | 434 |
| 149 | Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0188022 | 3.7 | 43 |
| 148 | Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. <i>BMC Cancer</i> , 2017 , 17, 505 | 4.8 | 124 |
| 147 | Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. <i>World Journal of Surgical Oncology</i> , 2017 , 15, 183 | 3.4 | 78 |

| | | | |
|-----|--|------|-----|
| 146 | Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017 , 35, 3671-3677 | 2.2 | 77 |
| 145 | Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, E65-E72 | 2.8 | 3 |
| 144 | An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 596-602 | 2.8 | |
| 143 | Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2017 , 60, 32-43 | 14.4 | 93 |
| 142 | A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , 2017 , 123, 4556-4565 | 6.4 | 40 |
| 141 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 825-835 | 27.4 | 235 |
| 140 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1028-1061 | 7.3 | 544 |
| 139 | Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , 2017 , 23, 6094-6100 | 12.9 | 107 |
| 138 | The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. <i>Cancer Causes and Control</i> , 2017 , 28, 959-969 | 2.8 | 42 |
| 137 | Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). <i>Cancer Journal (Sudbury, Mass)</i> , 2017 , 23, 350-354 | 2.2 | 9 |
| 136 | Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. <i>Oncologist</i> , 2017 , 22, 1429-e139 | 5.7 | 29 |
| 135 | Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncologica</i> , 2017 , 56, 1746-1753 | 3.2 | 23 |
| 134 | Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. <i>Acta Oncologica</i> , 2017 , 56, 384-390 | 3.2 | 20 |
| 133 | Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2135-2145 | 7 | 37 |
| 132 | Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4102-4102 | 2.2 | 4 |
| 131 | Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4110-4110 | 2.2 | 4 |
| 130 | Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15791-e15791 | 2.2 | 2 |
| 129 | Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9-9 | 2.2 | 1 |

| | | | |
|-----|---|------|-----|
| 128 | Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 279-279 | 2.2 | 14 |
| 127 | Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 343-343 | 2.2 | 16 |
| 126 | Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 370-370 | 2.2 | 5 |
| 125 | Pancreas adenocarcinoma: novel therapeutics. <i>Chinese Clinical Oncology</i> , 2017 , 6, 30 | 2.3 | 13 |
| 124 | Preface for Special Edition Pancreas Cancer. <i>Chinese Clinical Oncology</i> , 2017 , 6, 57 | 2.3 | |
| 123 | Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. <i>Gastroenterology</i> , 2016 , 150, 48-63 | 13.3 | 71 |
| 122 | Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 341-59 | 6.4 | 24 |
| 121 | Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016 , 122, 3765-3775 | 6.4 | 14 |
| 120 | Management of Metastatic Pancreatic Adenocarcinoma. <i>Surgical Clinics of North America</i> , 2016 , 96, 1391-1414 | 14.9 | |
| 119 | Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2784-96 | 2.2 | 205 |
| 118 | Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2398-403 | 2.2 | 128 |
| 117 | Early Detection and Treatment Opportunities in Pancreatic Adenocarcinoma. <i>Journal of Oncology Practice</i> , 2016 , 12, 31-2 | 3.1 | |
| 116 | Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 893-905 | 4.2 | 31 |
| 115 | Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. <i>Practical Radiation Oncology</i> , 2016 , 6, 78-85 | 2.8 | 24 |
| 114 | Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 24-31 | 3.8 | 9 |
| 113 | Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016 , 25, 311-26 | 2.7 | 18 |
| 112 | A novel scoring system to predict survival in patients with advanced pancreatic adenocarcinoma: The Memorial Prognostic Score (MPS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 36-36 | 2.2 | 1 |
| 111 | Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 437-437 | 2.2 | 3 |

| | | | |
|-----|---|------|-----|
| 110 | Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 738-749 | 2.8 | 11 |
| 109 | Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. <i>Pancreas</i> , 2016 , 45, 986-912. | 6 | 39 |
| 108 | Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy 2016 , | | 2 |
| 107 | Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 360-368 | 3.8 | 24 |
| 106 | ReCAP: Hospitalizations in Older Adults With Advanced Cancer: The Role of Chemotherapy. <i>Journal of Oncology Practice</i> , 2016 , 12, 151-2; e138-48 | 3.1 | 17 |
| 105 | Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. <i>Cell Reports</i> , 2016 , 16, 2017-31 | 10.6 | 65 |
| 104 | Novel Therapeutics for Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 777-87 | 3.1 | 11 |
| 103 | FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3512-21 | 3.1 | 112 |
| 102 | Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2015 , 14, 269-76.e1 | 3.8 | 17 |
| 101 | (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. <i>European Journal of Cancer</i> , 2015 , 51, 1857-64 | 7.5 | 20 |
| 100 | Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 585-601 | 4.2 | 3 |
| 99 | Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , 2015 , 121, 4382-8. | 4 | 117 |
| 98 | Lymph Node Metastasis Predicts Disease Recurrence in a Single-Center Experience of 70 Stages 1-3 Appendix Cancers: A Retrospective Review. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3613-7 | 3.1 | 17 |
| 97 | Intrahepatic cholangiocarcinoma: expert consensus statement. <i>Hpb</i> , 2015 , 17, 669-80 | 3.8 | 243 |
| 96 | Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma. <i>Seminars in Oncology</i> , 2015 , 42, 134-43 | 5.5 | 13 |
| 95 | Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. <i>Clinical Cancer Research</i> , 2015 , 21, 1313-20 | 12.9 | 189 |
| 94 | Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4114-4114 | 2.2 | 2 |
| 93 | Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 278-278 | 2.2 | 7 |

| | | | |
|----|--|------|-----|
| 92 | Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 358-358 | 2.2 | 1 |
| 91 | Liver-directed conversion therapy in metastatic colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 322-8 | 2.8 | 1 |
| 90 | "This is not me": patient, family, cultural and clinician considerations in cases of severe cancer-related debility. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 589-93 | 2.8 | |
| 89 | Liver resection for metastatic colorectal leiomyosarcoma: a single center experience. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, E70-6 | 2.8 | 10 |
| 88 | 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). <i>Journal of the National Cancer Institute</i> , 2014 , 106, | 9.7 | 25 |
| 87 | A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. <i>Pancreatology</i> , 2014 , 14, 398-402 | 3.8 | 13 |
| 86 | A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. <i>Annals of Surgery</i> , 2014 , 260, 142-8 | 7.8 | 100 |
| 85 | DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. <i>Pancreas</i> , 2014 , 43, 1264-70 | 2.6 | 27 |
| 84 | Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5281-9 | 12.9 | 42 |
| 83 | A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 60, 319-24 | 13.4 | 72 |
| 82 | Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4023-4023 | 2.2 | 16 |
| 81 | Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 220-220 | 2.2 | 4 |
| 80 | A woman with metastatic pancreatic neuroendocrine tumor. <i>Gastrointestinal Cancer Research: GCR</i> , 2014 , 7, 27-32 | | 2 |
| 79 | Liver and Bile Duct Cancer 2014 , 1373-1396.e8 | | 1 |
| 78 | Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?. <i>World Journal of Surgical Oncology</i> , 2013 , 11, 131 | 3.4 | 10 |
| 77 | Sunitinib malate for the treatment of pancreas malignancies--where does it fit?. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 783-92 | 4 | 9 |
| 76 | Adjuvant therapy for pancreas adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2013 , 107, 78-85 | 2.8 | 12 |
| 75 | A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients. <i>Journal of Palliative Medicine</i> , 2013 , 16, 623-31 | 2.2 | 63 |

| | | | |
|----|---|-----|----|
| 74 | Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. <i>Annals of Surgery</i> , 2013 , 258, 331-5 | 7.8 | 53 |
| 73 | Prognosis of minimally invasive carcinoma arising in mucinous cystic neoplasms of the pancreas. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 601-5 | 6.7 | 34 |
| 72 | Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 3-9 | | 46 |
| 71 | Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2013 , 6, 115-7 | | |
| 70 | Targeted agents and systemic therapy in hepatocellular carcinoma. <i>Recent Results in Cancer Research</i> , 2013 , 190, 225-46 | 1.5 | 18 |
| 69 | Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 159-159 | 2.2 | |
| 68 | Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 142-142 | 2.2 | |
| 67 | Emerging therapies for pancreas neuroendocrine cancers. <i>Chinese Clinical Oncology</i> , 2013 , 2, 23 | 2.3 | 6 |
| 66 | Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1663-9 | 3.1 | 45 |
| 65 | Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). <i>Cancer</i> , 2012 , 118, 571-8 | 6.4 | 17 |
| 64 | Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. <i>Journal of Neuro-Oncology</i> , 2012 , 106, 15-21 | 4.8 | 17 |
| 63 | Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature. <i>Human Pathology</i> , 2012 , 43, 1677-87 | 3.7 | 79 |
| 62 | A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. <i>PLoS ONE</i> , 2012 , 7, e40157 | 3.7 | 86 |
| 61 | Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. <i>Cancer</i> , 2012 , 118, 3053-61 | 6.4 | 62 |
| 60 | Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study. <i>Cancer</i> , 2012 , 118, 4331-8 | 6.4 | 52 |
| 59 | Costs and trends in pancreatic cancer treatment. <i>Cancer</i> , 2012 , 118, 5132-9 | 6.4 | 73 |
| 58 | Gastrointestinal cancer educational case series: a 65 year-old female with locally advanced gastric cancer and a supraclavicular lymph node. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43, 93-6 | 1.6 | |
| 57 | A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. <i>Journal of Gastrointestinal Cancer</i> , 2012 , 43, 314-8 | 1.6 | 1 |

| | | | |
|----|---|-----|-----|
| 56 | Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 609-13 | 2.2 | 11 |
| 55 | Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis. <i>Diseases of the Colon and Rectum</i> , 2012 , 55, 407-15 | 3.1 | 14 |
| 54 | Exocrine pancreas cancer and thromboembolic events: a systematic literature review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 835-46 | 7.3 | 14 |
| 53 | Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 298-298 | 2.2 | 4 |
| 52 | Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012 , 5, 130-4 | | 2 |
| 51 | A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. <i>Gastrointestinal Cancer Research: GCR</i> , 2012 , 5, 185-9 | | 7 |
| 50 | Synchronous epithelial and neuroendocrine cancers of the pancreas: case series of a rare occurrence. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 146-50 | 3.8 | 0 |
| 49 | Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 321-5 | 2.7 | 76 |
| 48 | A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2011 , 42, 160-4 | 1.6 | 11 |
| 47 | Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor. <i>Journal of Gastrointestinal Cancer</i> , 2011 , 42, 165-70 | 1.6 | 0 |
| 46 | A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management. <i>Journal of Gastrointestinal Cancer</i> , 2011 , 42, 236-40 | 1.6 | 0 |
| 45 | New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. <i>BioDrugs</i> , 2011 , 25, 207-16 | 7.9 | 7 |
| 44 | An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. <i>Oncologist</i> , 2011 , 16, 1397-402 | 5.7 | 190 |
| 43 | Building on Individual, State, and Federal Initiatives for Advance Care Planning, an Integral Component of Palliative and End-of-Life Cancer Care. <i>Journal of Oncology Practice</i> , 2011 , 7, 355-9 | 3.1 | 11 |
| 42 | Electronic Chemotherapy Order Entry: A Major Cancer Center's Implementation. <i>Journal of Oncology Practice</i> , 2011 , 7, 213-8 | 3.1 | 10 |
| 41 | Adjuvant therapy for pancreas adenocarcinoma: where are we going?. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 173-7 | 3.5 | 7 |
| 40 | Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. <i>Oncologist</i> , 2011 , 16, 1714-20 | 5.7 | 107 |
| 39 | Targeted Therapies for Hepatocellular Carcinoma 2011 , 355-368 | | |

| | | | |
|----|---|------|-----|
| 38 | Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3611-6 | 2.2 | 18 |
| 37 | Advanced hepatocellular carcinoma: which staging systems best predict prognosis?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2889-95 | 2.2 | 242 |
| 36 | A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). <i>Oncologist</i> , 2010 , 15, 1310-9 | 5.7 | 56 |
| 35 | Refinement of adjuvant therapy for pancreatic cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1124-5 | 27.4 | 20 |
| 34 | Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3605-10 | 2.2 | 499 |
| 33 | Pancreatic islet cell carcinoma presenting with concurrent Cushing's and Zollinger-Ellison syndromes: case series and literature review. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 246-52 | 2.2 | 6 |
| 32 | Hepatocellular carcinoma in two patients with cardiac cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 889-91 | 2.2 | 75 |
| 31 | Capsule-induced small-bowel obstruction during video capsule endoscopy in a patient with carcinomatosis. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1778-80 | 4 | 1 |
| 30 | Pancreatic adenocarcinoma in a young patient population--12-year experience at Memorial Sloan Kettering Cancer Center. <i>Journal of Surgical Oncology</i> , 2009 , 100, 8-12 | 2.8 | 23 |
| 29 | Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. <i>Investigational New Drugs</i> , 2009 , 27, 366-73 | 4.3 | 4 |
| 28 | Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. <i>Annals of Surgical Oncology</i> , 2009 , 16, 1751-6 | 3.1 | 224 |
| 27 | Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. <i>Cancer Investigation</i> , 2009 , 27, 402-6 | 2.1 | 1 |
| 26 | A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. <i>Pancreatology</i> , 2009 , 9, 404-9 | 3.8 | 32 |
| 25 | Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers. <i>Surgical Oncology Clinics of North America</i> , 2009 , 18, 361-79, x | 2.7 | 5 |
| 24 | Lack of splenic uptake of In-111 pentetate due to splenic embolization. <i>Clinical Nuclear Medicine</i> , 2009 , 34, 960-1 | 1.7 | |
| 23 | Accomplishments in 2008 in the management of localized pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S37-42 | | 2 |
| 22 | Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 140-3 | 3.8 | 3 |
| 21 | Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 402-5 | 3.8 | 7 |

| | | | |
|----|--|-----|-----|
| 20 | Comparison of gemcitabine plus platinum analog with gemcitabine alone in advanced pancreatic cancer. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 312-3 | | 2 |
| 19 | Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 875-80 | 3.5 | 41 |
| 18 | Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). <i>Journal of Surgical Oncology</i> , 2008 , 98, 485-9 | 2.8 | 286 |
| 17 | Liver and Bile Duct Cancer 2008 , 1569-1594 | | 1 |
| 16 | Cytotoxic therapy for advanced pancreatic adenocarcinoma. <i>Seminars in Oncology</i> , 2007 , 34, 347-53 | 5.5 | 61 |
| 15 | Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4441-7 | 2.2 | 235 |
| 14 | Biliary tract cancers: current concepts and controversies. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 211-23 | 4 | 25 |
| 13 | A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 334-9 | 2.7 | 8 |
| 12 | Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2926-32 | 2.2 | 84 |
| 11 | Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. <i>Cancer Investigation</i> , 2003 , 21, 512-6 | 2.1 | 20 |
| 10 | Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. <i>Annals of Surgical Oncology</i> , 2002 , 9, 954-60 | 3.1 | 62 |
| 9 | Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2157-70 | 2.2 | 144 |
| 8 | Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease 2002 , 9, 954 | | 2 |
| 7 | Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. <i>Annals of Surgical Oncology</i> , 2001 , 8, 787-95 | 3.1 | 111 |
| 6 | A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2001 , 91, 101-6. | 4 | 70 |
| 5 | Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1985-92 | 2.2 | 177 |
| 4 | Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer 2001 , 8, 787 | | 6 |
| 3 | A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. <i>Cancer Investigation</i> , 1999 , 17, 195-200 | 2.1 | 27 |

| | | | |
|---|--|-----|----|
| 2 | Non-Hodgkin lymphoma as a cause of intrahepatic periportal low attenuation on CT. <i>Journal of Computer Assisted Tomography</i> , 1997 , 21, 726-8 | 2.2 | 16 |
| 1 | Evolutionary Dynamics of Non-Coding Regions in Pancreatic Ductal Adenocarcinoma | | 1 |